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Background: Current asthma patient-reported outcome (PRO) measures focus on symptoms
and functioning and may not capture the holistic impact of asthma on the quality of life of
the patient.
Objective: Todevelopa PRO measurecapturing theoverall impact of asthma onpatient’s quality of
life.
Methods: Items for the Asthma Life Impact Scale (ALIS) were generated from patients with asthma
during interviews in the UK and focus groups in the US. The ALIS was tested with UK and US asthma
patientsduringcognitivedebriefing interviewsand included in large, two-administration,validation
studies in the UK and US.
Results: Issues raised by asthma patients during interviews (nZ 39 patients) and focus groups
(nZ 16 patients) were included in the draft ALIS. Cognitive debriefing interviews with 29 UK and
US asthma patients showed that the scale was relevant and comprehensive. 140 UK and 185 US
asthma patients participated in the validation study. The analysis showed that the ALIS measures
a single construct, namely the overall impact of asthma on patients’ quality of life. Internal consis-
tency (Cronbach’s Alpha) was high (UKZ 0.94; USZ 0.92) as was test-retest reliability (UKZ 0.93;
USZ 0.83). Patients reporting worse general health or more severe asthma had significantly higher
ALIS scores (p< 0.001) (indicatinggreaternegative impactofasthma).Correlationswith theAsthma
Quality of Life Questionnaire were moderate to high.act scale; AQLQ, Asthma quality of life questionnaire; IRT, Item response theory; RUMM, Rasch
QoL, Quality of life; PRO, patient-reported outcome.
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634 D.M. Meads et al.Conclusions: The final 22-item ALIS is unidimensional, reliable and valid, and a valuable tool for
comprehensively assessing the holistic impact of asthma from the patient’s perspective.
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Asthma represents a significant public health concern. It is
estimated to affect 300 million people globally and to have
accounted for approximately 255,000 deaths in 2005.1
People with asthma may experience more depression or
anxiety,2,3 lower life satisfaction and higher levels of
psychological distress4 than non-asthmatics. Asthma also has
significant negative implications for social relationships and
interaction,5,6 sex,7 employment8,9 and academic study.9
Clinical assessments of asthma such as lung function
tests and symptom assessments provide little information
about the overall impact of asthma on the patient’s life.
There is evidence that clinical assessments do not fully
capture the experience of living with the condition10 and
there are generally low levels of agreement between clin-
ical assessments and patient-reported outcomes
(PROs).11,12 Consequently, in order to gain a complete
picture of the impact of asthma on the patient, it is
important to assess patients’ heath-status and quality of
life (QoL) when evaluating treatment efficacy.
A comprehensive review of currently available, asthma-
specific QoL measures revealed that those most commonly
used e including the Asthma Quality of Life Questionnaire
(AQLQ),13 Airways Questionnaire (AQ20)14 and AQLQ-
Marks15 e are predominantly assessments of impairment
(symptoms), disability (functioning) and environmental
triggers, with emotional and QoL issues generally assessed
by a small proportion of the total items. For example, 6 out
of the 20 AQ20 questions could be considered to capture
the impact of asthma on QoL. Given this, it was decided to
develop a new asthma measure, the Asthma Life Impact
Scale (ALIS), that would comprehensively capture the
holistic impact of asthma on the QoL of the patient, from
the patient’s perspective. The aim was to produce a unidi-
mensional measure that could be used in combination with
existing PRO measures which capture the symptomatic and
functional impact of asthma.
Methods
The development of the ALIS involved three stages: quali-
tative, patient-led interviews and focus groups to derive
the scale content; cognitive debriefing of the draft ques-
tionnaire items; and a validation study to reduce the
number of items in the draft measure and to establish its
psychometric properties. The development of the ALIS was
undertaken in parallel in the UK and US. Ethics approval
was sought and gained in both countries and patients
recruited from clinics provided informed consent.
Qualitative interviews
The items for the ALIS were derived directly from patients
with asthma during in-depth, unstructured individualinterviews in the UK and focus group meetings in the US.
Patients with a diagnosis of asthma who were 18 or over
were included. Exclusion criteria included the presence of
COPD and any other major co-morbidity considered likely to
influence QoL. These co-morbidities were pre-defined and
included conditions such as cardiac failure, persistent
anaemia, cancer and major depression. Patients were
recruited using press advertisements in the UK and from US
clinics. The interviewees and focus group participants were
encouraged to talk at length about their experience of
asthma and the impact it had on all areas of their life.
Audio recordings were made of the interviews and focus
groups and content analysis applied to the transcripts in
order to derive the item pool. Each transcript was read by 2
experienced researchers independently with patients’
comments being highlighted and extracted if they repre-
sented expressions of how asthma affected their lives. The
needs-based quality of life model16e18 was used as the
conceptual framework for the ALIS. This model asserts that
QoL is dependent on an individual’s ability to fulfill funda-
mental needs and that QoL is high when these needs are
met. As far as possible the original words of the inter-
viewees were used to make the items more personal and
immediate to future respondents. Items were selected for
the draft ALIS if;
 they were applicable to all potential respondents,
 they reflected a single idea,
 they were unambiguous,
 they were short and simple,
 they were relevant to the needs model and
 they referred to issues raised by more than one
respondent.
The items were worded such that they would be
understood in the same way in the UK and US. The draft
measure would comprise of a list of statements which
patients consider and state whether it applies to them at
the moment using ‘True’/‘Not true’ response options.
Dichotomous response options were chosen as they are the
easiest to complete and score and have been shown to be
acceptable to patients.19 As the questionnaire asks patients
to respond thinking about how they feel at the moment it
negates concerns over the accuracy of recall, which are
especially pertinent when considering the recall of
emotions.20
Cognitive debriefing interviews
The draft ALIS was then tested by means of cognitive
debriefing interviews with people with asthma in the UK
and US. Interviewees were again aged 18 or over and were
recruited using advertisments in the UK and through clinics
in the US. The purpose of these one-to-one, semi-struc-
tured interviews was to examine the practicality, face and
Asthma life impact scale 635content validity of the ALIS. Patients were asked to
complete the draft ALIS in the presence of an interviewer.
They were then asked questions about ease of completion,
whether they could understand and answer the questions,
whether all important issues had been covered by the
questionnaire, whether any items appeared to be redun-
dant and about any problems that had been observed
during its completion.
Validation study
To reduce the number of items in the ALIS and assess its
scaling properties, reliability and construct validity, it was
necessary to analyse a large set of ALIS data. These data
were collected in studies conducted in the UK and US.
Patients were recruited through a UK District Hospital and
UK patient support groups and through four US clinics. As
with the first two stages of the study, patients were
included if they were aged 18 years or over and were
diagnosed with asthma. Patients were excluded if they
were unable to read and respond to questionnaires or if
they had co-morbidity deemed likely by the consulting
clinician to influence their QoL. Clinicians were given the
following examples of co-morbidity that should lead to
exclusion; COPD, cardiac failure, persistent anaemia,
cancer and major depression. Patients were required to
complete the ALIS on two occasions, two weeks apart. UK
patients filled-in the measure at home (posting back the
completed questionnaire) and US patients at visits to the
clinic. Patients also completed demographic questions,
a question asking how severe they perceived their asthma
to be (‘Mild’, ‘Moderate’, ‘Severe’ or ‘Very severe’) and
a question asking how they perceived their health to be in
general (‘Very good’, ‘Good’, ‘Fair’ or ‘Poor’). In the US the
clinicians were also asked how severe they thought their
patient’s asthma was (‘Mild’, ‘Moderate’ or ‘Severe’). The
level of severity was based on clinician report and thresh-
olds for lung volume tests were not provided. Patients in
the US were also asked if they had experienced an exac-
erbation (defined for the patient as being a worsening of
symptoms requiring an hospitalization or unscheduled visit
to a doctor) in the past week. Finally, patients completed
the AQLQ13 on both occasions.
Scaling and item reduction
The study data were then subjected to Rasch analysis21 for
final item reduction using the Rasch Unidimensional
Measurement Model (RUMM).22 The Rasch model used is
a one-parameter logistic item response theory (IRT) model
that is widely used in health outcome measurement.23e25
Rasch analysis is a key tool for the development and
improvement of questionnaires26 and has been shown to
have several advantages over traditional analyses such as
classical test theory and factor analysis.27e30
The Rasch model tests the assumption that the scale has
the basic property of unidimensionality and that all items
reflect a single underlying construct e in this instance the
holistic impact of asthma on QoL. Only when questionnaires
have been shown to be unidimensional is it acceptable to
add together individual item responses to derive a totalscore for each patient. The Rasch model gives each item in
the Scale and each respondent a location on the same
continuum of the construct or trait being captured; the
distance between these locations dictates the probability
that a person will affirm an item. For scales and items to be
working in the intended way (and thus fit the Rasch model)
there should be evidence that respondents with severe
disease (or high levels of the construct being measured e
asthma impact) are highly likely to affirm items repre-
senting mild levels of the construct and that respondents
with mild disease (low asthma impact) are highly unlikely to
affirm items representing high levels of the construct. The
Rasch model is explained in detail elsewhere.31,32
For a scale to be considered unidimensional local inde-
pendence of items is also necessary.33 Items that may be
influencing each other (suggesting multidimensionality) are
assessed by investigating correlations between item resid-
uals. Those with residual correlations above 0.3 may be
considered for removal.
Rasch analysis also provides the opportunity to assess
differential item functioning (DIF),34 that is, the extent to
which responses to individual items are affected by factors
that are external to the measurement tool (e.g. age and
gender). Finally, information about the extent to which the
levels of the construct experienced by the respondents are
accurately covered by the items is gained by viewing the
item maps. The item maps plot respondents and items on
the same continuum making it easy to identify gaps in
measurement. The maps also indicate the order of the
items in terms of their severity.
The fit of the overall ALIS and individual items to the
Rasch model was evaluated through Chi2 fit statistics with
non-significant results indicating fit to the model. If the data
are shown to fit the Rasch model and a solution is achieved,
a test for the absence of multidimensionality is conducted.35
For a scale to be unidimensional the responses to any subset
of the items should give the same estimate of person trait
level, given appropriate targeting. To try to break the
assumption of unidimensionality responses to 2 subsets of
items (loading most differently on first factor of the Residual
Principal Components Analysis) were assessed (using t-tests)
to see whether they produced significantly different esti-
mates for each respondent. If fewer than 5% of the t-tests
are significant then the measure may be considered to be
unidimensional. A 95% confidence interval is used to indicate
the reliability of the estimate.
The item reduction process was driven by item fit,
residuals, location and DIF. However, other aspects were
also considered, such as:
 item frequency rate (items with too low or too high
a rate of affirmation were considered for removal) and
 item-total correlations (item with correlations <0.2 or
>0.8 were considered for removal).
At the same time it was considered important to ensure
that the scale retained the face and content validity
established in the cognitive debriefing interviews. There-
fore, the content and meaning of the items were taken into
account before removal. Items that covered a unique issue
not captured by other items in the scale were not removed
unless it was unavoidable.
636 D.M. Meads et al.The item reduction process was an iterative one since fit
to the Rasch model is influenced by the removal of every
item. Therefore items were removed individually and the
analyses re-run.
Reliability, reproducibility and construct validity
After the final version of the ALIS was derived the following
traditional psychometric properties of the scale were
assessed:
 Internal consistency: Cronbach’s alpha coefficients
were calculated. A value less than 0.70 indicates that
individual items provide an inadequate contribution to
the overall scale.36
 Test-retest reliability: Spearman’s rank correlations of
the ALIS scores at the two administrations were calcu-
lated. Intra-class correlations were also calculated. A
high correlation (above 0.80 for population studies37)
indicates that the scale produces an acceptably low
level of random measurement error.
Convergent and divergent validity were evaluated by
assessing the level of association (Spearman rank correla-
tions) between scores on the ALIS and those on the AQLQ. It
was hypothesised that higher correlations would be found
between the ALIS and AQLQ Emotional and Activity scales
than between the ALIS and the AQLQ Environmental stimuli
scale.
Discriminative validity was assessed by examining ALIS
scores of respondents who differed according to their self-Table 1 Study sample characteristics.
Interview/focus group
sample
UK US
Sample size 39 16
Number (%) male 14 (36%) 8 (50%)
Mean (SD) age (years) 49 (17.6) 37 (10.6
Age range (years) 22e82 22e60
Mean (SD) duration of asthma (years) 21 (14.4) 19 (12.8
Duration of asthma range (years)a 0e68 e
Patient perceived severity of asthma
Mild (%) 21 (53.8%) 6 (38.0
Moderate (%) 10 (25.6%) 4 (25.0
Severe (%) 4 (10.3%) 6 (38.0
Very severe (%) 3 (7.7%) 0
Perceived general health
Very good (%) 5 (12.8%) e
Good (%) 14 (35.9%) e
Fair (%) 15 (38.5%) e
Poor (%) 5 (12.8%) e
Asthma exacerbation in last week?
Yes (%) e e
No (%) e e
a 1 UK interviewee, 2 US cognitive debriefing interviewees and 11 US
1 year.rated asthma severity, self-perceived current general
health and (in the US only) clinician rating of asthma
severity and whether they had experienced an exacerba-
tion in the previous week. ALIS scores were also compared
for groups who differed according to their employment
status, self-reported presence of anxiety or depression and
treatment type. Non-parametric tests for independent
samples (ManneWhitney U Test for two groups and
KruskaleWallis Test for three or more groups) were
employed to test for differences.
Psychometric testing was completed using the SPSS 15.0
statistical package.Results
Qualitative interviews
Qualitative interviews and focus groups were conducted
with (nZ 39 UK and nZ 16 US) patients with asthma. The
UK sample included 14 (36%) males and had an average age
of 49 (range 22e82) while the US sample included 8 (50%)
males and had an average age of 37 (range 22e60). See
Table 1 for full demographic details. Interviews lasted
between 1 and 3.5 h and focus groups were 1.5 h in
duration.
It was clear that asthma has a considerable detrimental
impact on the lives of patients. Table 2 summarises aspects of
patients’ lives that are affected by asthma. The table also
includes comments made by patients and associated draft
ALIS items. Figure 1 represents the conceptual frameworkCognitive debriefing
interview sample
Validation sample
UK US UK US
16 13 140 185
9 (56%) 3 (23%) 41 (29%) 48 (26%)
) 52 (17.7) 46 (17.2) 51 (16.2) 46 (15.9)
29e82 18e73 18e83 18e85
) 24 (14.7) 21 (18.2) 21 (16.2) 18 (15.3)
6e60 0e46 1e71 0e66
%) 9 (56.3%) e 50 (35.7%) 95 (51.4%)
%) 6 (37.5%) e 54 (38.6%) 64 (34.5%)
%) 1 (6.3%) e 26 (18.6%) 17 (9.2%)
0 e 8 (5.7%) 3 (1.6%)
2 (12.5%) e 17 (12.1%) 28 (15.1%)
8 (50.0%) e 49 (35%) 93 (50.3%)
4 (25.0%) e 54 (38.6%) 50 (27%)
2 (12.5%) e 19 (13.6%) 8 (4.3%)
e e e 11 (5.9%)
e e e 166 (89.7%)
validation survey participants had an asthma duration of less than
Table 2 Example comments from patients and draft items.
Example patient quotes Issue Associated need Draft item
‘‘I don’t like going out in case I start coughing and you want
to bring phlegm up especially if you’re in a group of
people having a meal or something e it’s not nice’’
Embarrassment/Reduced desire
to socialise
Social/relationships It restricts my social activities
‘‘It affects our sex life yeah, because I get very breathless’’ Sex/Personal relationships Relationships/Affection It affects my close relationships
‘‘The only problem is with people walking past me when I
was sat down and thinking that I am lazy’’
Reduced capabilities/Reduced
self-esteem
Self-actualisation/
self-esteem
I worry that other people will think
I0m lazy
‘‘I couldn’t physically get up the stairs..I was like an old
woman and this really upset me’’
Reduced self-esteem Self-esteem I feel older than my years
‘‘There are a lot of times when I think, I can control it, but
then it starts controlling me’’
Loss of control Control My illness controls me
‘‘I don’t know what state my lungs will be in, I don’t know
how they’ll react being in that country or that altitude.’’
Loss of spontaneity/Need to plan Independence/Control I find it difficult to make plans
‘‘It is a bit worrying for me, if I have got asthma and it
progressively gets worse as I get older’’
Fear and worry Safety and security I worry about my asthma getting worse
‘‘It feels e uhm e well you are losing your independence
aren’t you? It makes you less dependent on yourself’’
Independence Independence I feel I0m a burden to others
‘‘Because my asthma is on my mind all the time I can’t push
myself to my limit’’
Reduced capabilities Self-actualisation It stops me reaching my full potential
‘‘I have to plan activities around my treatments’’ Loss of spontaneity/dependence
on treatment
Independence/Control I have to plan activities around my
treatment
‘‘So you get very wary of trying new things, it stops me
being adventurous’’
Loss of spontaneity/Reduced
capabilities
Self-actualisation Asthma stops me being adventurous
‘‘It is all consuming, you can’t think of anything else.’’ Preoccupation with asthma Control My asthma is always on my mind
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Figure 1 ALIS conceptual framework.
Table 3 Results of Item reduction process.
Stage Number
of items
Reasons for item
removal/addition
Qualitative
interviews
2070
Assessed other outcome
constructs,
Duplicated other items,
Idiosyncratic,
Poorly worded,
Unsuitable for
miscellaneous reasons
Cognitive
debriefing
interviews
38
Addition of item on
interest in sex
2 items too severe
1 item ambiguous
Validation
survey
36
2 items too severe
1 item high itemetotal
correlation
3 items misfit in UK and US
3 items misfit in UK only
1 item misfit in UK and US
1 item misfit in UK only
1 item misfit in US only
2 items misfit revealed
after removal of above
12 items
Final ALIS 22
638 D.M. Meads et al.for the ALIS and the issues raised by patients within the
framework of the needs-based model.
Content analysis of the interview data identified over
2000 potential items for the measure. The item pool was
reduced by removing duplicated and other unsuitable
items. This left a draft version of the ALIS containing 38
items (Table 3).
Cognitive debriefing interviews
Patients with asthma in the UK (n Z 16) and US (n Z 13)
participated in cognitive debriefing interviews. The UK
sample included 9 (56%) males and had an average age of 52
(range 29e82) while the US sample included 3 (23%) males
and had an average age of 46 (range 18e73). See Table 1 for
full demographic details.
All respondents were clear about the purpose of the
interview and all participants completed all of the items.
Similarly, none of the respondents had any difficulty with
the instructions.
Overall, patients in both countries found the question-
naire clear and easy to complete. One respondent apolo-
gised for frequently answering ‘not true’ because his
asthma was so mild that, to him, most of the items were
‘irrelevant’. In fact, he answered ‘true’ to 9 of the 38
items. Two respondents said that the item I can’t think of
anything but my asthma was irrelevant to them. It is likely
that this item was not ‘irrelevant’ for these individuals but
merely ‘not true’, as their Asthma was mild. Two respon-
dents did not feel that the scale was relevant. One stated
that he did not want asthma to control his life, indicating
that this was not a redundant issue. The other commented
Asthma life impact scale 639that the measure was too extreme e again suggesting that
his asthma did not have a major impact on his QoL.
Only a few changes to the questionnaires were required
(Table 3). For example, an item relating to sex (My asthma
affects my interest in sex) was added as this omission was
mentioned by one interviewee. Checking back to the orig-
inal qualitative interview transcripts found that this issue
had been raised indirectly by four interviewees. Three
items were removed as they were too severe (affirmed by
none of the respondents) or were misinterpreted. The
wording of five items was changed from ‘It’ to ‘My asthma’
(for example in the item, My asthma limits the places I can
go) as US respondents found it difficult to respond to items
that did not specify the disease e even though this is clearly
explained in the instructions.
Validation study
The new draft ALIS was then completed by patients with
asthma (n Z 140 UK patients via post and n Z 185 US
patients during clinic visits) on two occasions, approxi-
mately two weeks apart (demographic details are included
in Table 1).
Scaling and item reduction
Data from the UK and US were separately applied to the
Rasch model. Two items were removed due to a low item
frequency rate and one due to a high item-total correla-
tion. A further 11 items were removed from the scale due
to misfit or DIF (see Table 3). The same items were retained
in the US and UK so that e apart from minor wording
differences e the US and UK scales would be the same. The
final 22-item ALIS fit the Rasch model in the UK and the US
(Chi2 p > 0.01 in both countries; see Table 4). Only one item
(‘I have to pace myself’ in the UK) misfit the Rasch model.
However, this item was retained because it did not misfit at
the second time point. One pair of items showed local
dependence in both countries. However, participants in the
cognitive debriefing interviews suggested that the two
items described different issues and wanted both to be
included in the scale.
Only one patient in the combined samples had a high fit
residual.
When UK and US data were combined there was minimal
DIF according to country. Tests confirmed that both the UK
and US ALIS were unidimensional. The unidimensional t-test
results shown in Table 4 indicate that the assumption of
unidimensionality cannot be broken. Investigation of
residual correlations showed that 2 item pairs in the UK and
1 item pair in the US had residual correlations above 0.3.
These item pairs were further investigated and it was foundTable 4 ALIS: Overall Rasch fit statistics.
n ItemeTrait
Interaction Chi2
PSI ItemePerson
Items
Mean
UK 132 0.05 0.92 0.60
US 170 0.02 0.90 0.41that while these item pairs measure related concepts they
are conceptually different and have different locations on
the logit scale.
The item maps indicated that the ALIS has a good spread
of items on the underlying trait. The items assessing the
greatest level of construct (the most severe items) in both
the UK and US were ‘I feel isolated because of my asthma’
and ‘My asthma affects my close relationships’ and the
three mildest items in both countries were ‘I feel depen-
dent on my treatment’, ‘I have to pace myself’ and ‘My
asthma makes me cautious of where I go’. The item
ordering, location and overall range of coverage were
similar in each country (see Table 5).
Scores on the final version of the ALIS can range from
0 to 22 with a high score indicating that asthma has a major
negative impact on the QoL of the respondent.
Internal consistency and reliability
The Cronbach’s Alpha and test-retest coefficients were
acceptable for both the UK and US Scales (Table 6).
Convergent validity
The ALIS correlations were highest in the UK and US with
the AQLQ Activities scale, reflecting that activity limitation
plays an important role in the overall impact of asthma on
patients’ daily life. ALIS scores had the lowest correlations
with the AQLQ Environment scale in both countries.
There were no significant correlations between ALIS
scores and age or duration of asthma in the UK or with age
in the US (data not shown). There was a small but statis-
tically significant correlation between ALIS scores and
duration of illness in the US (r Z 0.22; p Z 0.004).
Discriminative validity
Table 7 includes ALIS scores by known group factors and
Figure 2 illustrates ALIS scores by severity and general
health ratings. The ALIS was able to distinguish between
respondents according to (patient- and clinician-rated)
asthma severity, perceived general health and whether or
not they had experienced an exacerbation over the
previous week. In all cases patients reporting more severe
asthma or worse health had significantly (p < 0.01) higher
ALIS scores than those reporting milder asthma or better
health. Significantly higher scores were also found for those
not working due to their asthma and those with self-
reported mental health problems.
Discussion
This study was designed to develop a patient-reported
outcome measure e the ALIS e that comprehensivelyinteraction Unidimensional t-test
results (CI)Persons
SD Mean SD
0.93 0.32 0.82 0.03 (0.01e0.07)
1.12 0.25 0.82 0.04 (0.01e0.08)
Table 5 Rasch item fit statistics.
Item Location Fit
residual
Chi2 p
UK
Dependent on
treatment
2.61 0.07 4.5 0.11
Need to pace activities 2.25 0.85 11.5 0.00
Cautious where go 1.49 0.36 3.1 0.22
Prevents visiting 1.44 0.98 1.5 0.47
Need for energy 1.44 1.00 1.5 0.48
Limits potential 0.9 1.29 2.8 0.25
Preoccupation with
medication
0.35 1.39 4.3 0.12
Limit activities 0.33 1.73 3.3 0.19
Inability to be
adventurous
0.14 1.57 2.6 0.27
Limit social activities 0.08 2.44 3.3 0.19
Feel old 0.10 0.75 0.2 0.92
Interest in sex 0.37 0.60 1.9 0.39
Let others down 0.64 0.84 0.3 0.85
Preoccupation with
asthma
0.67 0.55 3.8 0.15
Self-confidence 0.68 0.59 2.0 0.38
Lowered mood 0.80 1.30 3.4 0.18
Social limitations 0.90 0.93 0.2 0.93
Controlled by illness 1.05 0.64 1.4 0.51
Planning activities 1.14 0.83 1.2 0.56
Appear lazy 1.15 0.13 0.0 0.98
Affects relationships 1.19 0.86 1.1 0.57
Feel isolated 2.33 1.29 7.0 0.03
US
Need to pace activities 2.53 0.06 1.5 0.46
Dependent on
treatment
2.09 1.56 3.2 0.20
Cautious where go 1.70 0.19 0.6 0.76
Need for energy 1.54 1.03 1.4 0.51
Limits potential 1.02 1.96 7.7 0.02
Prevents visiting 0.94 0.06 0.1 0.97
Inability to be
adventurous
0.76 2.11 4.6 0.10
Preoccupation with
medication
0.32 0.34 3.5 0.17
Feel old 0.25 1.48 5.1 0.08
Limit activities 0.18 1.85 5.8 0.05
Limit social activities 0.12 1.94 2.7 0.26
Appear lazy 0.00 0.45 0.7 0.72
Social limitations 0.49 0.05 2.9 0.23
Preoccupation with
asthma
0.75 1.39 4.3 0.12
Let others down 0.86 0.46 3.1 0.21
Lowered mood 0.88 1.05 1.7 0.43
Planning activities 0.99 0.68 5.8 0.06
Self-confidence 1.24 1.19 4.5 0.10
Interest in sex 1.27 0.07 2.5 0.28
Controlled by illness 1.39 0.86 1.3 0.53
Affects relationships 1.48 1.23 1.6 0.44
Feel isolated 2.09 1.02 2.1 0.35
Table 6 Reliability of the ALIS and correlations with the
AQLQ.
UK ALIS n US ALIS n
Reliability coefficients
Alpha 0.94 128 0.92 182
Test-retest 0.93 63 0.83 53
ICC 0.92 63 0.82 53
Correlations with AQLQ
Symptoms 0.75** 119 0.70** 179
Activities 0.84** 100 0.80** 178
Environment 0.53** 121 0.60** 182
Emotion 0.72** 122 0.71** 181
Total 0.79** 95 0.78** 174
**Correlation p < 0.01 (2-tailed).
640 D.M. Meads et al.captures the holistic impact of asthma and its treatment on
the quality of life of patients. It is intended that the ALIS
will be used alongside more traditional measures of symp-
toms and functional capacity to allow patients to describe
the full impact of their condition.
There has been much debate about the nature of QoL
assessments, and no consensus has been reached on how
QoL should be defined or assessed.38 Some researchers
consider QoL to be multidimensional, comprising at least
three factors (usually social, emotional and physical).
However, it is unclear how some issues raised by patients
with asthma in this study e relating to limited self-actual-
isation, loss of independence and autonomy and loss of
spontaneity, for example e would fit into such a frame-
work. In addition, many issues raised by patients do not fit
neatly into just one of these categories. For example, ifTable 7 Discriminative validity e mean ALIS scores by
sub-group.
UK US
n Mean (SD) n Mean (SD)
Gender
Male 36 7.1 (6.7) 47 6.2 (5.5)
Female 91 9.3 (6.9) 131 6.7 (5.8)
P 0.09 0.67
Employment
Working 59 6.5 (6.0) 126 5.8 (4.7)
Not working
due to asthma
16 16.6 (5.8) 16 16.2 (6.0)
P <0.001 <0.001
Exacerbation in last week?
No e e 166 6.0 (5.18)
Yes e e 11 14.5 (5.84)
P <0.001
Self-reported mental health problems
No anxiety or
depression
e e 125 5.5 (4.9)
Anxiety e e 20 8.2 (6.4)
Depression e e 14 8.6 (6.1)
Anxiety and depression e e 18 10.2 (7.4)
p e 0.011
Figure 2 ALIS scores by asthma severity and general health
ratings.
Asthma life impact scale 641a patient is unable to participate in activities with their
friends due to their asthma they have impaired physical
functioning but this also has social and emotional implica-
tions for them. The use of the needs-based QoL conceptual
framework overcomes the need to have a separate subscale
for each factor under consideration and gives an overall
picture of the impact of the disease. The use of item
response theory techniques (in this study, Rasch analysis)
allows the development of a scale that can be shown
empirically to capture a single trait or construct.
As the items in the Scale were derived directly from
qualitative research in patients with asthma and capture
issues of importance to them, the ALIS has high face and
content validity. Patients contributing to the items in the
ALIS spanned the asthma severity range thus ensuring that
the measure will be acceptable to future respondents
regardless of how much their lives are impacted by asthma.
It is short, quick and easy to complete and score, hence it
lends itself to inclusion in clinical studies.
The ALIS has excellent psychometric properties as it was
shown to be reliable and valid in both the UK and US. The
fact that the ALIS was validated using clinic-based admin-
istration in the US and administration via postal survey in
the UK e and had satisfactory psychometric properties in
both e indicates that it is suitable to administer the ques-
tionnaire using either mode.
The ALIS exhibited moderate to large correlations with
the AQLQ. Despite the magnitude of these coefficients the
results indicate that the AQLQ (total score) explains only
62% and 61% of the UK and US ALIS scores, respectively e
highlighting that they are measuring distinct aspects of the
asthma experience. The ALIS exhibited the lowestcorrelations with the environmental stimuli scale of the
AQLQ in the UK and US, suggesting that triggers are not the
most accurate indicator of the impact of asthma.
The ALIS was able to discriminate between patients
according to their severity and general health groups
providing further evidence of its validity. Differences were
also apparent in ALIS scores according to self-reported
mental health problems. Previous research has highlighted
the influence of anxiety and depression on QoL and health
status questionnaire scores in asthma.39,40 Further research
is necessary to establish how and to what extent depression
and anxiety affect scores on the ALIS. It is also desirable
that the correlation between ALIS scores and a patient-
reported measure of asthma control is established. Given
the burden placed on patients in the current study it was
not possible to include a measure of control in addition to
the questionnaires used.
One limitation of the study is that little clinical valida-
tion of the ALIS data was undertaken. However, the anal-
yses showed that the ALIS was able to distinguish between
patients who had and had not experienced a clinical
worsening (necessitating hospitalisation or an unscheduled
visit to a doctor) in the previous week and differentiated
between patients according to the clinician’s rating of
severity. In addition, significant differences in ALIS scores
were observed based on types of treatment received.
Respondents using treatments associated with severe
asthma (anticholinergics and corticosteroids) had signifi-
cantly higher scores on the ALIS than those not using these
treatments. These results help to interpret the meaning of
ALIS scores and to understand the impact of asthma on
quality of life. For example, patients who had experienced
an exacerbation or needed to use anticholinergics and
corticosteroids had ALIS scores over twice the magnitude of
those who did not have an exacerbation or did not use
either treatment.
Another limitation is that a proportion of the patients in
the UK validation study were recruited through advertising.
In these cases it was not possible to confirm that they had
asthma or that they did not have concomitant COPD.
Furthermore, clinics were not given consistent criteria to
diagnose COPD when deciding whether or not to exclude
participants.
It is important to note that the samples studied are
unlikely to be representative of the asthma population as
a whole. No attempt was made to stratify disease severity,
age or gender as this was not necessary in order to validate
the ALIS. That said, the study samples included a reason-
able spread in terms of patient ages and asthma severity.
Since the time between questionnaire administrations in
the study was only 2 weeks there was very little change
observed in scores over time. This precluded the assessment
of the responsiveness of the ALIS to changes in the status of
the patient and represents another study limitation.
However, studies are planned that will enable the determi-
nation of the responsiveness of the ALIS, the thresholds of
changes in score that are considered clinically important and
the association between ALIS scores and clinical variables.
The ALIS represents a new instrument measuring the
overall impact that asthma has on patients; this is a valu-
able tool that will complement symptom and functioning
patient-reported outcomes.
642 D.M. Meads et al.Summary
 Quality of life is an important outcome in asthma that is
distinct from symptoms and functional capacity e the
focus of many current patient-reported outcome
questionnaires.
 Asthma has a significant and broad impact on the
quality of life of those affected.
 A key to understanding this impact is the accurate
assessment of quality of life.
 The research describes the development of a new
questionnairee the Asthma Life Impact Scalee that will
allow this assessment from the patient’s perspective.
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